研究单位：[1]I-Mab Biopharma Co. Ltd.[2]The second affiliated hospital of Kunming medical university Yunnan,Kunming,China,650101[3]The First People's Hospital of Yunnan Province Yunnan,Kunming,China,650221[4]The First Hospital of Lanzhou University Lanzhou,Lanzhou,China,730000[5]Lanzhou University Second Hospital Lanzhou,Lanzhou,China,730030[6]Second Affiliated Hospital of Nanchang University Jiangxi,Nanchang,China,330006[7]Nanjing Drum Tower Hospital Nanjing,Nanjing,China,210008[8]Jiangsu Province Hospital Nanjing,Nanjing,China,210029[9]Guangxi Medical Univ. 1st Hospital Guangxi,Nanning,China,530021
研究目的：
A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received at least 1 prior line of treatment
